These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
267 related articles for article (PubMed ID: 26699228)
1. Pharmaceutical excipients - quality, regulatory and biopharmaceutical considerations. Elder DP; Kuentz M; Holm R Eur J Pharm Sci; 2016 May; 87():88-99. PubMed ID: 26699228 [TBL] [Abstract][Full Text] [Related]
2. Lipid excipients and delivery systems for pharmaceutical development: a regulatory perspective. Chen ML Adv Drug Deliv Rev; 2008 Mar; 60(6):768-77. PubMed ID: 18077051 [TBL] [Abstract][Full Text] [Related]
3. The Effects of Pharmaceutical Excipients on Gastrointestinal Tract Metabolic Enzymes and Transporters-an Update. Zhang W; Li Y; Zou P; Wu M; Zhang Z; Zhang T AAPS J; 2016 Jul; 18(4):830-43. PubMed ID: 27184579 [TBL] [Abstract][Full Text] [Related]
4. Potential for pharmaceutical excipients to impact absorption: A mechanistic review for BCS Class 1 and 3 drugs. Flanagan T Eur J Pharm Biopharm; 2019 Aug; 141():130-138. PubMed ID: 31128247 [TBL] [Abstract][Full Text] [Related]
6. Excipient pharmacokinetics and profiling. Loftsson T Int J Pharm; 2015 Mar; 480(1-2):48-54. PubMed ID: 25596414 [TBL] [Abstract][Full Text] [Related]
7. In vitro evaluation of extemporaneously compounded immediate-release capsules with premixed excipients, based on the biopharmaceutics classification system (BCS) of the drugs. Pinheiro VA; Danopoulos P; Demirdjian L; Nogueira RJ; Dubois F Int J Pharm Compd; 2013; 17(5):424-31. PubMed ID: 24459788 [TBL] [Abstract][Full Text] [Related]
8. Excipient variability and its impact on dosage form functionality. Dave VS; Saoji SD; Raut NA; Haware RV J Pharm Sci; 2015 Mar; 104(3):906-15. PubMed ID: 25561249 [TBL] [Abstract][Full Text] [Related]
9. Pharmaceutical excipient development: the need for preclinical guidance. Baldrick P Regul Toxicol Pharmacol; 2000 Oct; 32(2):210-8. PubMed ID: 11067777 [TBL] [Abstract][Full Text] [Related]
11. Excipients in parenteral formulations: selection considerations and effective utilization with small molecules and biologics. Rayaprolu BM; Strawser JJ; Anyarambhatla G Drug Dev Ind Pharm; 2018 Oct; 44(10):1565-1571. PubMed ID: 29863908 [TBL] [Abstract][Full Text] [Related]
12. A PAT-based qualification of pharmaceutical excipients produced by batch or continuous processing. Hertrampf A; Müller H; Menezes JC; Herdling T J Pharm Biomed Anal; 2015 Oct; 114():208-15. PubMed ID: 26072012 [TBL] [Abstract][Full Text] [Related]
13. The role of formulation on the pharmacokinetics of antiretroviral drugs. Bastiaans DE; Cressey TR; Vromans H; Burger DM Expert Opin Drug Metab Toxicol; 2014 Jul; 10(7):1019-37. PubMed ID: 24877605 [TBL] [Abstract][Full Text] [Related]
14. The effects of excipients on transporter mediated absorption. Goole J; Lindley DJ; Roth W; Carl SM; Amighi K; Kauffmann JM; Knipp GT Int J Pharm; 2010 Jun; 393(1-2):17-31. PubMed ID: 20417699 [TBL] [Abstract][Full Text] [Related]
15. Best practices for selection of excipients for paediatrics - Workshop reflection. Salunke S; Clapham D; Agrawal A; Hughes K; Nunn T Eur J Pharm Biopharm; 2021 Mar; 160():77-81. PubMed ID: 33400989 [TBL] [Abstract][Full Text] [Related]
16. Biopharmaceutical aspects and implications of excipient variability in drug product performance. Zarmpi P; Flanagan T; Meehan E; Mann J; Fotaki N Eur J Pharm Biopharm; 2017 Feb; 111():1-15. PubMed ID: 27845182 [TBL] [Abstract][Full Text] [Related]
17. Pediatric drug development: formulation considerations. Ali AA; Charoo NA; Abdallah DB Drug Dev Ind Pharm; 2014 Oct; 40(10):1283-99. PubMed ID: 24483293 [TBL] [Abstract][Full Text] [Related]
18. Interactions between active pharmaceutical ingredients and excipients affecting bioavailability: impact on bioequivalence. García-Arieta A Eur J Pharm Sci; 2014 Dec; 65():89-97. PubMed ID: 25236823 [TBL] [Abstract][Full Text] [Related]
19. Investigating the Discriminatory Power of BCS-Biowaiver in Vitro Methodology to Detect Bioavailability Differences between Immediate Release Products Containing a Class I Drug. Colón-Useche S; González-Álvarez I; Mangas-Sanjuan V; González-Álvarez M; Pastoriza P; Molina-Martínez I; Bermejo M; García-Arieta A Mol Pharm; 2015 Sep; 12(9):3167-74. PubMed ID: 26287948 [TBL] [Abstract][Full Text] [Related]